Myelopeptide-2 recovers interleukin-2 synthesis and interleukin-2 receptor expression in human T lymphocytes depressed by tumor products or measles virus

Journal of Immunotherapy

Volumn 29, Issue 3, 2006, Pages 306-312

  Mikhailova, Augusta A ^a   Belevskaya, Raissa G ^a   Kalyuzhnaya, Maria ^a   Fonina, Larissa A ^a   Liashenko, Vsevolod A ^b   Petrov, Rem V ^a  

^a SHEMYAKIN OVCHINNIKOV INSTITUTE OF BIOORGANIC CHEMISTRY   (Russian Federation)

^b Institute of Viral Preparations   (Russian Federation)

Author keywords

Immunocorrection; Interleukin 2 production; Interleukin 2 receptor expression; Myelopeptides; T lymphocytes

Indexed keywords

CYTOKINE; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; LEUCYLVALYLVALYLTYROSYLPROLYLTRYPTOPHAN; MYELOPEPTIDE; UNCLASSIFIED DRUG; GAMMA INTERFERON; MYELOPEPTIDES; OLIGOPEPTIDE; TUMOR ANTIGEN;

ARTICLE; BONE MARROW CELL; CELL STRAIN HL 60; CONTROLLED STUDY; CYTOKINE PRODUCTION; HOMEOSTASIS; HUMAN; HUMAN CELL; LEUKEMIA CELL; MEASLES VIRUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; TH1 CELL; TH2 CELL; CELL PROLIFERATION; IMMUNE SYSTEM; LYMPHOCYTE ACTIVATION; METABOLISM; NEOPLASM;

ANTIGENS, NEOPLASM; CELL PROLIFERATION; CYTOKINES; HL-60 CELLS; HUMANS; IMMUNE SYSTEM; INTERFERON TYPE II; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; MEASLES VIRUS; NEOPLASMS; OLIGOPEPTIDES; RECEPTORS, INTERLEUKIN-2; T-LYMPHOCYTES;

EID: 33746067547     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cji.0000188366.84341.c3     Document Type: Article

References (24)

1. Paul S, Calmels B, Regulier E. Tumor-induced immunosuppression. Ann Biol Clin (Paris). 2002;60:143-152.
2. Kapadia SB, Levine B, Speck SH, et al. Critical role of complement and viral evasion complement in acute, persistent, and latent g-herpes virus infection. Immunity. 2002;17:1-20.
3. Marincola FM, Jaffe EM, Hicklin DJ, et al. Escape of human solid tumors from T cell recognition: molecular mechanisms and functional significance. Adv Immunol. 2000;74:181-273.
4. Carcelain G, Rouas-Freiss N, Zorn E, et al. In situ T-cell responses in a primary regressive melanoma and subsequent metastases: a comparative analysis. Int J Cancer. 1997;72:241-247.
5. Anichini A, Mortarini R, Maccalli C, et al. Cytotoxic T cells directed to tumor antigens not expressed on normal melanocytes dominate HLA-A2.1-restricted immune repertoire to melanoma. J Immunol. 1996;156:208-217.
6. Sheu B-C, Lin R-H, Lien H-C, et al. Predominant Th2/Tc2 polarity of tumor-infiltrating lymphocytes in human cervical cancer. J Immunol. 2001;167:2972-2978.
7. Chouaib S, Asselin-Paturel C, Mami-Chouaib F, et al. The host-tumor immune conflict: from immunosuppression to resistance and destruction. Immunol Today. 1997;18:493-497.
8. Chiao JW, Heil M, Arlin Z, et al. Suppression of lymphocyte activation and functions by a leukemia cell-derived inhibitor. Proc Natl Acad Sci USA. 1986;83:3432-3436.
9. Petrov RV, Mikhailova AA, Fonina LA, et al. Myelopeptides. Singapore: World Scientific; 1999.
10. Mikhailova A, Fonina L, Kirilina E, et al. Immunoregulatory properties of hexapeptide isolated from porcine bone marrow cell culture. Regul Pept. 1994;53:203-209.
11. Petrov RV, Mikhailova AA, Fonina LA. Bone marrow immunoregulatory peptides (myelopeptides): isolation, structure, and functional activity. Biopolymers. 1997;43:139-145.
12. Mikhailova AA, Fonina AL, Kirilina E, et al. Peculiarities of immunocorrective effect of the bone marrow regulatory peptides (myelopeptides). Regul Pept. 2003;114:183-187.
13. Strelkov LA, Mikhailova AA, Sapozhnikov AM, et al. The bone marrow peptide (myelopeptide-2) abolishes induced by human leukemia HL-60 cell suppression of T-lymphocytes. Immunol Lett. 1996;50:143-147.
14. Fonina LA, Ovchinnikov MV, Gur'yanov SA, et al. Synthesis and properties of retro-analogue myelopeptide-2 [in Russian]. Bioorg. Khim. 2005;31:1-6.
15. Reed LJ, Muench H. A simple method of estimating fifty percent endpoints. Am J Hyg. 1938;27:493-497.
16. Miescher S, Whiteside TL, Carrel S, et al. Functional properties of tumor-infiltrating and blood lymphocytes in patients with solid tumors: effects of tumor cells and their supernatants on proliferative responses of lymphocytes. J Immunol. 1986;136:1899-1907.
17. Maeyer E, Maeyer-Guigharg J. Interferons. In: Thompson A, ed. The Cytokine Handbook. 3rd ed. Academic Press: Boston, San Diego, USA; 1998:491-516.
18. Griffin DE, Ward BJ, Esolen LM, et al. Pathogenesis of measles virus infection: a hypothesis for altered immune responses. J Infect Dis. 1994;170(Suppl 1):24-31.
19. Leopardi R, Ilonen J, Mattila L, et al. Effect of measles virus infection on MHC class II expression and antigen presentation in human monocytes. Cell Immunol. 1993;147:388-396.
20. Clerici M, Shearer GM. The Th1/Th2 hypothesis of HIV infection: new insights. Immunol Today. 1994;15:575-581.
21. Lucey DR, Clerici M, Shearer GM. Type 1 and Type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases. Clin Microbiol Rev. 1996;9:532-562.
22. Smyth MJ, Swann J, Kelly JM, et al. NKG2D recognition and perforin effector function mediate effective cytokine immunotherapy of cancer. J Exp Med. 2004;200:1325-1335.
23. Thompson JA, Lee DJ, Lindgren CG, et al. Influence of dose and duration of infusion of interleukin 2 on toxicity and immunomodulation. J Clin Oncol. 1988;6:669-678.
24. Khabarov SV, Gerasimova GK, Mikhailova AA, et al. MP-2 induces a resistance of T lymphocytes to tumor-induced suppression [in Russian]. Dokl Akad Nauk. 2003;390:268-271.